Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Nephrology

Standard of Care Treatment Strategies

At a Glance

Treatment for autosomal dominant nephropathy with hypertension centers on blood pressure control, kidney-protective medicines, lower sodium intake, exercise, and avoiding NSAIDs such as ibuprofen. Some people with rapidly progressing ADPKD may benefit from tolvaptan with regular monitoring.

Managing autosomal dominant progressive nephropathy with hypertension requires a dual focus: controlling blood pressure to protect the heart and slowing the decline of kidney function to delay or prevent the need for dialysis [1][2].

Because this is a lifelong condition, treatment is not about a “quick fix” but rather a series of protective measures that adapt as your kidney function changes.

The Foundation: ACE Inhibitors and ARBs

For many people with inherited kidney disease, a class of blood pressure medications called ACE inhibitors (like lisinopril) or ARBs (like losartan) is highly useful [3]. These drugs do more than just lower blood pressure; they specifically relax the blood vessels within the kidneys, reducing the internal pressure that causes scarring and protein leakage [4][5]. However, they are not universally appropriate for everyone; the choice depends on your specific disease, albuminuria, eGFR, potassium, and pregnancy status.

  • Monitoring: When you start or change these medications, your doctor will check your blood work soon after to monitor your potassium levels and creatinine [6][7].
  • Dual Therapy: Doctors generally avoid prescribing both an ACE inhibitor and an ARB at the same time, as this “dual blockade” can increase the risk of side effects without providing extra protection [5].

Targeting Blood Pressure

Current international guidelines (KDIGO) conditionally recommend a target systolic blood pressure (the top number) of less than 120 mmHg for many adults with CKD, provided it is measured using standardized office techniques and is tolerated well [1][8]. However, this target is highly individualized. If you are older, frail, or experience orthostatic symptoms (dizziness when standing), your doctor may aim for a slightly higher target to avoid falls [9][10]. Do not adjust your target on your own.

Lifestyle as Medicine

Small, consistent changes in your daily routine can significantly impact how quickly your disease progresses:

  • Sodium Restriction: Aiming for less than 2,000 mg of sodium per day from all foods is a cornerstone of care [11][12]. Note that sodium and salt are not exactly the same thing (one teaspoon of table salt contains roughly 2,300 mg of sodium), and much sodium comes from processed foods. Lowering sodium intake makes blood pressure medications work more effectively [13].
  • Physical Activity: Regular aerobic exercise, tailored to your ability, helps manage blood pressure and protects your cardiovascular health [14][15].
  • Avoiding Nephrotoxins: Your kidneys are more sensitive to certain substances. It is generally recommended to avoid NSAIDs (non-steroidal anti-inflammatory drugs) like ibuprofen or naproxen, as they can cause a sudden drop in kidney function [16].
  • Individualized Diet: A plant-dominant diet may be helpful, but you should work with a renal dietitian to ensure you are getting the right balance of sodium, potassium, and protein for your specific kidney stage [17][2].

Disease-Specific Treatments

If genetic testing provides a precise diagnosis, your doctor may add targeted therapies to your plan:

  • Tolvaptan (for ADPKD): If you have confirmed ADPKD and are demonstrably at risk for rapid progression, tolvaptan can slow the growth of cysts and the decline of kidney function [18][19].
    • Side Effects: This medication causes significant thirst and very frequent, heavy urination, posing a risk of marked dehydration [20][21].
    • Liver Safety: Because of a rare risk of liver injury, patients on tolvaptan must have liver blood tests at baseline, early in treatment, monthly for the first 18 months, and at longer intervals thereafter [22][23].
    • Pregnancy: Tolvaptan also requires pregnancy-specific counseling and contraception.
  • SGLT2 Inhibitors: While increasingly common for diabetes or albuminuric CKD, major kidney-protection trials generally have not established benefit specifically for ADPKD. Their use should be individualized.
  • Other Targets: For conditions like ADTKD related to a UMOD or REN mutation, treatment may focus specifically on managing gout or anemia alongside blood pressure control [24][25].

The Importance of “Sick-Day” Management

When you are on kidney-protective medications, a simple stomach flu can become serious. If you become dehydrated from vomiting, diarrhea, or fever, do not make permanent or unsupervised changes. Instead, work with your doctor now to create an individualized written sick-day plan identifying which medicines (like ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors) to hold, when to seek urgent advice, and when to restart them [7][26].

Common questions in this guide

How do ACE inhibitors and ARBs help protect the kidneys?
ACE inhibitors and ARBs lower blood pressure and relax blood vessels inside the kidneys, which can reduce pressure-related scarring and protein leakage. They are not usually taken together, and clinicians typically check creatinine and potassium after starting or changing one.
What blood pressure goal is used for this kidney condition?
For many adults with chronic kidney disease, guidelines conditionally suggest a systolic blood pressure below 120 mmHg when it is measured with a standardized office technique and tolerated. The target may be higher for older or frail people or anyone who becomes dizzy when standing, so do not change it without medical guidance.
Which lifestyle changes can help slow inherited kidney disease?
Limiting sodium to less than 2,000 mg per day, exercising regularly as tolerated, and avoiding NSAIDs such as ibuprofen or naproxen can support blood pressure and kidney health. A renal dietitian can help tailor sodium, potassium, and protein intake to your stage of kidney disease.
Could tolvaptan help if I have ADPKD?
Tolvaptan may be considered for some people with confirmed ADPKD who are at demonstrable risk of rapid progression. It can cause intense thirst and frequent, heavy urination, and it requires liver blood tests, hydration planning, and pregnancy-specific counseling.
What should I do with my medicines if vomiting or diarrhea causes dehydration?
Ask your clinician in advance for a written sick-day plan. It should explain whether to temporarily hold medicines such as an ACE inhibitor, ARB, diuretic, or SGLT2 inhibitor, when to seek urgent advice, and when to restart treatment. Do not make permanent or unsupervised medication changes.
Are SGLT2 inhibitors appropriate for inherited kidney disease?
SGLT2 inhibitors are increasingly used for diabetes or kidney disease with albuminuria, but major kidney-protection trials have not established a specific benefit for ADPKD. Whether one is appropriate depends on your exact diagnosis and other medical factors, so the decision should be individualized with your clinician.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my protein levels, should I be taking an ACE inhibitor or an ARB to protect my kidneys?
  2. 2.What is my target blood pressure, taking into account my age, specific diagnosis, and any symptoms of dizziness?
  3. 3.If my genetic testing confirms ADPKD, would I be a candidate for tolvaptan, and what would the monitoring schedule for my liver look like?
  4. 4.Can you provide a written 'sick-day protocol'—which medications should I temporarily stop if I get a stomach flu or become dehydrated?
  5. 5.Are SGLT2 inhibitors appropriate for my specific type of inherited kidney disease?
  6. 6.Is it safe for me to use over-the-counter anti-inflammatory drugs (NSAIDs) like ibuprofen, or should I avoid them entirely?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (26)
  1. 1

    Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease.

    Cheung AK, Chang TI, Cushman WC, et al.

    Kidney international 2021; (99(3)):559-569 doi:10.1016/j.kint.2020.10.026.

    PMID: 33637203
  2. 2

    Chronic kidney disease.

    Kalantar-Zadeh K, Jafar TH, Nitsch D, et al.

    Lancet (London, England) 2021; (398(10302)):786-802 doi:10.1016/S0140-6736(21)00519-5.

    PMID: 34175022
  3. 3

    [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors].

    Egocheaga MI, Drak Y, Otero V

    Semergen 2023; (49 Suppl 1()):102018 doi:10.1016/j.semerg.2023.102018.

    PMID: 37355297
  4. 4

    Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials.

    Mishima E, Haruna Y, Arima H

    Hypertension research : official journal of the Japanese Society of Hypertension 2019; (42(4)):469-482 doi:10.1038/s41440-018-0116-3.

    PMID: 30948820
  5. 5

    Efficacy and safety of dual vs single renin-angiotensin-aldosterone system blockade in chronic kidney disease: An updated meta-analysis of randomized controlled trials.

    Zhao M, Qu H, Wang R, et al.

    Medicine 2021; (100(35)):e26544 doi:10.1097/MD.0000000000026544.

    PMID: 34477114
  6. 6

    Hyperkalemia After Initiating Renin-Angiotensin System Blockade: The Stockholm Creatinine Measurements (SCREAM) Project.

    Bandak G, Sang Y, Gasparini A, et al.

    Journal of the American Heart Association 2017; (6(7)) doi:10.1161/JAHA.116.005428.

    PMID: 28724651
  7. 7

    Acute Kidney Injury in Elderly Patients With Chronic Kidney Disease: Do Angiotensin-Converting Enzyme Inhibitors Carry a Risk?

    Chaumont M, Pourcelet A, van Nuffelen M, et al.

    Journal of clinical hypertension (Greenwich, Conn.) 2016; (18(6)):514-21 doi:10.1111/jch.12795.

    PMID: 27080620
  8. 8

    A European Renal Association (ERA) synopsis for nephrology practice of the 2023 European Society of Hypertension (ESH) Guidelines for the Management of Arterial Hypertension.

    Sarafidis P, Schmieder R, Burnier M, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2024; (39(6)):929-943 doi:10.1093/ndt/gfae041.

    PMID: 38365947
  9. 9

    KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Blood Pressure in CKD.

    Drawz PE, Beddhu S, Bignall ONR, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2022; (79(3)):311-327 doi:10.1053/j.ajkd.2021.09.013.

    PMID: 35063302
  10. 10

    Pros and cons of lower blood pressure targets in chronic kidney disease.

    Hernandez MF, Chang TI

    Current opinion in nephrology and hypertension 2026; (35(2)):150-155 doi:10.1097/MNH.0000000000001153.

    PMID: 41460077
  11. 11

    Managing Hypertension in Chronic Kidney Disease: The Role of Diet and Guideline Recommendations.

    Stambolliu E, Iliakis P, Tsioufis K, Damianaki A

    Journal of clinical medicine 2025; (14(11)) doi:10.3390/jcm14113755.

    PMID: 40507517
  12. 12

    [Progression inhibition in chronic kidney disease].

    Weinmann-Menke J, Galle J

    Innere Medizin (Heidelberg, Germany) 2026; (67(8)):836-842 doi:10.1007/s00108-026-02145-x.

    PMID: 42397586
  13. 13

    Sodium Intake and Chronic Kidney Disease.

    Borrelli S, Provenzano M, Gagliardi I, et al.

    International journal of molecular sciences 2020; (21(13)) doi:10.3390/ijms21134744.

    PMID: 32635265
  14. 14

    Primary and Secondary Prevention of Cardiovascular Disease in Patients with Chronic Kidney Disease.

    Ali S, Dave N, Virani SS, Navaneethan SD

    Current atherosclerosis reports 2019; (21(9)):32 doi:10.1007/s11883-019-0794-6.

    PMID: 31230129
  15. 15

    Hypertension management in patients with advanced chronic kidney disease with and without dialysis.

    Gonzalez Suarez ML, Arriola-Montenegro J, Rolón L

    Current opinion in cardiology 2025; (40(4)):199-205 doi:10.1097/HCO.0000000000001221.

    PMID: 40183393
  16. 16

    [Management of Patients with CKD in Clinical Practice].

    Dabers T, Weckmann G, Chenot JF, Stracke S

    Deutsche medizinische Wochenschrift (1946) 2017; (142(17)):1290-1298 doi:10.1055/s-0043-108466.

    PMID: 28850966
  17. 17

    Fruits, Vegetables, and Legumes: Harnessing the Gut-Kidney Axis in Hypertensive Chronic Kidney Disease.

    Agustin M, Hadinata E, Harbuwono DS, et al.

    Foods (Basel, Switzerland) 2026; (15(16)) doi:10.3390/foods15162938.

    PMID: 42650632
  18. 18

    Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

    Torres VE, Higashihara E, Devuyst O, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2016; (11(5)):803-811 doi:10.2215/CJN.06300615.

    PMID: 26912543
  19. 19

    Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease.

    Blair HA

    Drugs 2019; (79(3)):303-313 doi:10.1007/s40265-019-1056-1.

    PMID: 30689194
  20. 20

    Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.

    Devuyst O, Chapman AB, Shoaf SE, et al.

    Kidney international reports 2017; (2(6)):1132-1140 doi:10.1016/j.ekir.2017.07.004.

    PMID: 29270521
  21. 21

    Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial.

    Shoaf SE, Chapman AB, Torres VE, et al.

    Journal of clinical pharmacology 2017; (57(7)):906-917 doi:10.1002/jcph.880.

    PMID: 28218410
  22. 22

    Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.

    Watkins PB, Lewis JH, Kaplowitz N, et al.

    Drug safety 2015; (38(11)):1103-13 doi:10.1007/s40264-015-0327-3.

    PMID: 26188764
  23. 23

    Multicenter Study of Long-Term Safety of Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.

    Torres VE, Chapman AB, Devuyst O, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2020; (16(1)):48-58 doi:10.2215/CJN.10250620.

    PMID: 33376102
  24. 24

    Familial juvenile hyperuricemia in early childhood in a boy with a novel gene mutation.

    Takemasa Y, Hirano D, Kawakami Y, et al.

    CEN case reports 2021; (10(3)):426-430 doi:10.1007/s13730-020-00566-7.

    PMID: 33616882
  25. 25

    Hyperuricemia and elevated creatinine in a child with anemia.

    Leventoğlu E, Şimşek A, Keçeci HN

    The Turkish journal of pediatrics 2025; (67(6)):904-911 doi:10.24953/turkjpediatr.2025.6313.

    PMID: 41636190
  26. 26

    Tolvaptan in Autosomal Dominant Polycystic Kidney Disease (ADPKD): a multicenter real life Italian experience.

    Econimo L, Toso D, Capasso G, et al.

    Clinical kidney journal 2025; (18(11)):sfaf156 doi:10.1093/ckj/sfaf156.

    PMID: 41377852

This page is for informational purposes only and does not constitute medical advice. A nephrologist or other qualified clinician should personalize your medicines, blood-pressure target, diet, and sick-day instructions.

Get notified when new evidence is published on Autosomal dominant progressive nephropathy with hypertension.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.